Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01240460
First received: November 11, 2010
Last updated: July 26, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection. XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.


Condition Intervention Phase
Glioblastoma
Astrocytoma, Grade IV
Drug: XL765 (SAR245409)
Drug: XL147 (SAR245408)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To explore the biological effect of XL765 and XL147 measured by modulation of PI3K/ mTOR pathway readouts in GB tumor tissue [ Time Frame: Assessed between 10 and 28 days after initiation of study drug ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To examine the safety profile of daily oral administration of XL765 and XL147 in subjects with recurrent GB [ Time Frame: Assessed at every visit to the study clinic for the duration of subject's treatment ] [ Designated as safety issue: Yes ]
  • To determine the levels of XL765 and XL147 in plasma and GB tumor tissue [ Time Frame: Assessed at periodic visits between 10 and 28 days after initiation of study drug for the duration of subject's treatment ] [ Designated as safety issue: No ]
  • To assess the anti-proliferative and pro-apoptotic effects of XL765 and XL147 on tumor cells [ Time Frame: Assessed at periodic visits to the study clinic for the duration of subject's treatment ] [ Designated as safety issue: No ]
  • To measure changes in tumor after surgery in subjects receiving XL765 and XL147 [ Time Frame: Assessed at periodic visits following surgery 10 to 28 days after initiation of study drug for the duration of subject's treatment ] [ Designated as safety issue: No ]
  • To conduct genetic analyses of GB tumor tissue comparing, where feasible, tumor tissue removed during the on-study resection with tissue removed during the initial surgical resection [ Time Frame: Assessed 10 to 28 days after initiation of study drug ] [ Designated as safety issue: No ]
  • To evaluate the pharmacodynamic effects of XL765 and XL147 in blood and/or blood cells for identification and characterization of surrogate biomarkers associated with the biological effects of XL765 and XL147 [ Time Frame: Assessed at periodic visits to the study clinic ] [ Designated as safety issue: No ]
  • To explore the relationship between clinical response and genomic and proteomic biomarkers in the PI3K and EGFR pathways [ Time Frame: Duration of the study (approximately 2 years) ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: January 2011
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Twice-daily dosing (every 12 hours) XL765
Drug: XL765 (SAR245409)
Supplied as 10-mg and/or 50-mg capsules
Experimental: 2
Once-daily dosing XL147
Drug: XL147 (SAR245408)
Supplied as 100-mg, 150-mg and/or 200-mg tablets
Experimental: 3
Once-daily dosing XL765
Drug: XL765 (SAR245409)
Supplied as 10-mg and/or 50-mg capsules

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject has histologically confirmed diagnosis of primary GB for which the subject has received prior treatment, including radiation and/or chemotherapy, and will be undergoing a second surgical resection.
  2. The subject has available archival tumor tissue from the time of initial diagnosis of GB that is designated for central laboratory analysis.
  3. The subject is ≥ 18 years old.
  4. The subject has a Karnofsky performance status (KPS) ≥ 60%.
  5. The subject has adequate organ and marrow function.
  6. The subject has adequate fasting plasma glucose levels and glycosylated hemoglobin levels.
  7. The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.
  8. Sexually active subjects (men and women) must agree to use medically-accepted barrier methods of contraception during the course of the study and for 3 months after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control.
  9. Women of childbearing potential must have a negative pregnancy test at screening.

Exclusion Criteria:

  1. The subject has confirmed secondary GB (ie, had a pathology-confirmed lower-grade glioma that subsequently recurred as a higher grade glioma).
  2. The subject's tumor has a predominance of WHO Grade IV oligoastrocytoma.
  3. The subject has received radiation therapy for GB within 12 weeks (≤ 84 days) before their first dose of study drug treatment.
  4. The subject has received specific types of anticancer therapy (should be discussed with the treating physician)
  5. The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Grade ≤ 1 from AEs due to surgery, radiation, antineoplastic agents, investigational drugs, or other medications that were administered before screening (except Grade 2 alopecia and Grade 2 lymphocytopenia).
  6. The subject is receiving > 1 mg/day warfarin (or equivalent of other coumarin derivatives) and is unable to switch to low molecular weight heparin within 14 days before the first dose of study drug.
  7. The subject is receiving enzyme-inducing anti-epileptic agents (EIAED; eg, carbamazepine, phenytoin, phenobarbital, or primidone) or valproic acid and is unable to convert to EIAED anti-seizure agents within 14 days before the first dose of study drug.
  8. The subject has uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Hypertension (consistent blood pressure readings of > 140 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment
    • Significant cardiac arrhythmias, or a recent history of serious disease, such as either symptomatic congestive heart failure or unstable angina pectoris within 3 months, or the following events within 6 months: myocardial infarction, stroke, or transient ischemic attack.
    • Inherited or acquired bleeding diathesis
  9. The subject has a baseline corrected QT interval (QTc) > 460 ms.
  10. The subject is unable to undergo repeated magnetic resonance imaging (MRI) scans for any reason (eg, cardiac pacemaker or ferromagnetic metal implants).
  11. The subject is known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is not required for eligibility.
  12. The subject has impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study treatment (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  13. The subject is pregnant or breastfeeding.
  14. The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01240460

Locations
United States, California
Investigational Site Number 840001
Los Angeles, California, United States, 90024
Investigational Site Number 840003
San Francisco, California, United States, 94143
United States, Massachusetts
Investigational Site Number 840004
Boston, Massachusetts, United States, 02115
United States, New York
Investigational Site Number 840002
New York, New York, United States, 10021
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01240460     History of Changes
Other Study ID Numbers: TED11605, XL765-202
Study First Received: November 11, 2010
Last Updated: July 26, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Astrocytoma
Glioblastoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors

ClinicalTrials.gov processed this record on November 25, 2014